A prospective,obsevational study to evaluate association between polymorphism and safety in patients wth Colon cancer naive to treatment with Regorafenib

Trial Profile

A prospective,obsevational study to evaluate association between polymorphism and safety in patients wth Colon cancer naive to treatment with Regorafenib

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colon cancer; Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2017 New trial record
    • 03 Feb 2017 Preliminary results (n=37) published in the International Journal of Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top